Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings

Cancer. 1982 Jun 1;49(11):2222-5. doi: 10.1002/1097-0142(19820601)49:11<2222::aid-cncr2820491103>3.0.co;2-5.

Abstract

Fifteen patients with acute nonlymphocytic leukemia (ANLL) who either had a relapse after a previous complete remission (nine patients) or progressive disease after initial induction attempts with combination chemotherapy (six patients) were treated with 5-azacytidine. Five patients (33%) achieved a complete remission (CR); of these, three had a relapse and died 30, 35, and 38 weeks after 5-azacytidine therapy was begun. Two patients are still alive at 39 and 138 weeks. Chromosomes were analyzed at the time of diagnosis; ten patients had a normal karyotype and five had an abnormal karyotype. Three of the five CR patients had an abnormal karyotype initially. Two of these individuals had a translocation of chromosomal material from a No. 8 chromosome to a No. 21 chromosome, t(8;21); this particular translocation has been associated with a better prognosis than have other types of chromosomal abnormalities in patients with ANLL. Even when abnormal chromosomes are present, 5-azacytidine can induce complete remission in patients with previously treated ANLL.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Azacitidine / therapeutic use*
  • Bone Marrow / pathology
  • Chromosome Aberrations
  • Chromosome Disorders
  • Chromosomes, Human, 21-22 and Y
  • Chromosomes, Human, 6-12 and X
  • Female
  • Follow-Up Studies
  • Humans
  • Karyotyping
  • Leukemia, Lymphoid / drug therapy*
  • Leukemia, Lymphoid / genetics
  • Male
  • Middle Aged
  • Translocation, Genetic

Substances

  • Azacitidine